Displaying drugs 11701 - 11725 of 11734 in total
R-30490
R-30490 is an opioid related to carfentanil used as an animal tranquilizer. It was first synthesized by Janssen Pharmaceutica as part of a structure-activity relationship study of fentanly and its derivatives. R-30490 was found to be the most selective agonist for the mu opioid receptor out of all the fentanyl...
Experimental
Matched Description: … It was first synthesized by Janssen Pharmaceutica as part of a structure-activity relationship study …
Golotimod
SCV-07 (g -D-glutamyl-L-tryptophan) is a novel synthetic dipeptide that acts broadly on the Toll-like receptor pathway. It has been shown to stimulate T-lymphocyte differentiation, macrocytic phagocytosis, and specific immune responses, and enhance IL-2 and INF-g production. Due to this preferential activation of Th1 cytokine production, SCV-07 may show utility in...
Investigational
Matched Description: … SCV-07 (g -D-glutamyl-L-tryptophan) is a novel synthetic dipeptide that acts broadly on the Toll-like …
CoronaVac
CoronaVac, previously known as PiCoVacc, is a SARS-CoV-2 purified, inactivated, and adsorbed vaccine candidate developed by SinoVac Biotech Corporation . It was developed by propagating the SARS-CoV-2 CN2 strain inside Vero Cells and inactivating it with B-propiolactone[A219481;A219758]. In preclinical trials, PiCoVacc induced SARS-CoV-2-specific neutralizing antibodies in rats, mice, and the...
Investigational
Matched Description: … CoronaVac, previously known as PiCoVacc, is a SARS-CoV-2 purified, inactivated, and adsorbed vaccine …
RG-7795
Investigational
Dihydroquinidine barbiturate
Experimental
LY-517717
LY517717 is an investigational oral direct inhibitor of activated Factor Xa. It is believed to be Lilly's PMD-3112 (licensed from Amgen).
Investigational
Lefradafiban
Lefradafiban is an oral platelet glycoprotein IIb/IIIa receptor antagonist being investigated in the treatment of angina.
Investigational
Batimastat
Experimental
NP-50301
NP-50301 is an ophthalmic therapeutic eye drop treating post-menopausal Dry Eye Syndrome (DES). It is being developed by Nascent Pharmaceuticals. It is estimated that about 30% of postmenopausal women suffer symptoms of DES, which accounts for over 12 million women in the U.S. The majority of sufferers of DES are...
Investigational
HY10275
HY10275 is a novel compound specifically designed to modulate two key neurobiological mechanisms that interfere with the sleeping process. HY10275 is highly selective for histamine H1 and serotonin 5HT2a, two chemical receptors that are known to impact the ability to fall asleep and stay asleep. HY10275 was rationally designed to...
Investigational
Matched Description: … HY10275 is a novel compound specifically designed to modulate two key neurobiological mechanisms that …
Epofolate
Epofolate has been used in trials studying the treatment of Advanced Solid Tumors. Epofolate (BMS-753493) is a folate conjugate of the epothilone analog BMS-748285 that was designed to selectively target folate receptor expressing cancer cells. In Phase I/IIa pharmacokinetic and safety studies epofolate was generally tolerable and toxicities known to...
Investigational
Matched Description: … Epofolate (BMS-753493) is a folate conjugate of the epothilone analog BMS-748285 that was designed to …
Ohmefentanyl
Ohmefentanyl is an extremely potent opioid analgesic drug which selectively binds to the µ-opioid receptor. The Chinese have recorded ohmefentanyl as having a potency that is 6,300 times morphine. Ohmefentanyl is one of the most potent μ -receptor agonists known, comparable to super-potent opioids such as carfentanil and etorphine which...
Illicit
Matched Description: … The Chinese have recorded ohmefentanyl as having a potency that is 6,300 times morphine. …
IRL-1620
SPI-1620 is an endothelin B receptor agonist. In animal models SPI-1620 selectively and transiently increases tumor blood flow allowing increased delivery of anticancer agents to the tumor. It is being developed as an adjunct to chemotherapy.
Investigational
PR-104
Investigational
Elvucitabine
Investigational
Tunicamycin
Tunicamycin is a mixture of homologous nucleoside antibiotics that inhibits the UDP-HexNAc: polyprenol-P HexNAc-1-P family of enzymes. One member of this family is the enzyme GlcNAc phosphotransferase (GPT), which catalyzes the transfer of N-acetylglucosamine-1-phosphate from UDP-N-acetylglucosamine to dolichol phosphate in the first step of glycoprotein synthesis in eukaryotes. Tunicamycin blocks...
Experimental
Matched Description: … Tunicamycin is a mixture of homologous nucleoside antibiotics that inhibits the UDP-HexNAc: polyprenol-P …
Placental Mesenchymal Stem Cells
The placenta serves many purposes, with one of the many being a bank of mesenchymal stem cells (MSCs). It can be obtained relatively easily as medical waste from which MSCs can be non-invasively extracted and without the ethical issues that come with embryonic stem cells. The placental MSCs (pMSCs) are...
Investigational
Matched Description: … The placenta serves many purposes, with one of the many being a bank of mesenchymal stem cells (MSCs) …
Covax-19™
Covax-19™, a protein-based vaccine, was developed through partnership between APC and Vaxine. It uses an insect-cell-produced recombinant SARS-CoV-2 spike protein and Vaxine’s adjuvant, Advax-SM. This adjuvant is designed to circumvent high fevers, fatigue, and aches experienced with other vaccines using more traditional adjuvants. Covax-19™ was tested in animal studies, and...
Investigational
Matched Description: … Covax-19™, a protein-based vaccine, was developed through partnership between APC and Vaxine. …
Etesevimab
Etesevimab (LY-CoV016, also known as JS016) is a fully human and recombinant monoclonal antibody that targets the SARS-CoV-2 surface spike protein receptor binding domain.[L16651,L16661] Under the EUA granted in February 2021, etesevimab is used in combination with bamlanivimab to treat mild to moderate COVID-19 in adults and pediatric patients who...
Investigational
Matched Description: … Etesevimab (LY-CoV016, also known as JS016) is a fully human and recombinant monoclonal antibody that …
DDP-200
DDP200 is developed by Dynogen for the treatment of non-incontinent form of overactive bladder (OAB) with particular focus on both male and female patients with urinary frequency, urinary urgency and nocturia.
Investigational
Tabelecleucel
Tabelecleucel is an innovative therapy that uses Epstein-Barr virus (EBV)-specific allogeneic cytotoxic T cells (CTLs). It is produced by mixing T-cells with B-cells that have been infected with the Epstein-Barr virus (EBV). Both T-cells and B-cells are obtained from the same donor, and T-cells are grown to increase their numbers....
Investigational
Matched Description: … When given to a patient with EBV-associated post-transplant lymphoproliferative disorder (PTLD) following …
Eniluracil
Eniluracil, which was previously under development by GlaxoSmithKline (GSK), is being developed by Adherex to enhance the therapeutic value and effectiveness of 5-fluorouracil (5-FU), one of the world’s most widely-used oncology agents. 5-FU is widely used in the U.S. and is often first or second line therapy for a variety...
Investigational
Matched Description: … widely-used oncology agents. 5-FU is widely used in the U.S. and is often first or second line therapy for a …
Shark liver oil
Shark oil is extracted from the livers of sharks, which can account for up to 25% of their total body weight. The 3 main targeted species are the deep sea shark (Centrophorus squamosus), the dogfish (Sqaulus acanthias), and the basking shark (Cetorhinus maximus). Shark oil is a rich source of...
Experimental
Matched Description: … Shark oil is a rich source of alkylglycerols and squalene, with relatively low amounts of n-3 polyunsaturated …
SEP-363856
SEP-363856 is a novel psychotropic drug being investigated for the treatment of schizophrenia. Unlike other drugs used for this condition, SEP-363856 does not bind to the dopamine D2 receptors, but exerts actions on the trace amine–associated receptor 1 (TAAR1) and 5-hydroxytryptamine type 1A (5-HT1A). SEP-363856 was developed by Sunovion pharmaceuticals....
Investigational
Matched Description: … SEP-363856 is a novel psychotropic drug being investigated for the treatment of schizophrenia. …
SNS-032
Investigational
Displaying drugs 11701 - 11725 of 11734 in total